ID   NALM-1
AC   CVCL_0091
SY   Nalm-1; NALM 1; NALM1; Nalm1
DR   CLO; CLO_0007937
DR   EFO; EFO_0002244
DR   CLDB; cl3630
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; CRL-1567
DR   BioSample; SAMN01821583
DR   BioSample; SAMN01821650
DR   BioSample; SAMN03471397
DR   CCLE; NALM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
DR   CGH-DB; 9216-4
DR   Cosmic; 787506
DR   Cosmic; 801721
DR   Cosmic; 908157
DR   Cosmic; 999775
DR   Cosmic; 1012105
DR   Cosmic; 1026573
DR   Cosmic; 1498418
DR   Cosmic; 2491099
DR   DSMZ; ACC-131
DR   GEO; GSM887346
DR   GEO; GSM888422
DR   IGRhCellID; NALM1
DR   JCRB; JCRB0064
DR   Wikidata; Q54907391
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=301573;
RX   PubMed=302341;
RX   PubMed=3332852;
RX   PubMed=6582512;
RX   PubMed=9067587;
RX   PubMed=9680106;
RX   PubMed=12506034;
RX   PubMed=15588857;
RX   PubMed=15843827;
RX   PubMed=16408098;
RX   PubMed=20215515;
RX   PubMed=22460905;
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Doubling time: ~48 hours (DSMZ).
CC   Omics: Deep RNAseq analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Discontinued: JCRB; JCRB0064; probable.
CC   Derived from sampling site: Peripheral blood.
ST   Source(s): ATCC; DSMZ
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11,12
ST   D16S539: 11,15
ST   D5S818: 11
ST   D7S820: 10,11
ST   TH01: 7,9
ST   TPOX: 9,11
ST   vWA: 15,17
DI   NCIt; C7320; Childhood chronic myelogenous leukemia, BCR-ABL1 positive
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   3Y
CA   Cancer cell line
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=301573; DOI=10.1093/jnci/59.1.83;
RA   Minowada J., Tsubota T., Greaves M.F., Walters T.R.;
RT   "A non-T, non-B human leukemia cell line (NALM-1): establishment of
RT   the cell line and presence of leukemia-associated antigens.";
RL   J. Natl. Cancer Inst. 59:83-87(1977).
//
RX   PubMed=302341; DOI=10.1093/jnci/59.3.833;
RA   Sonta S.-I., Minowada J., Tsubota T., Sandberg A.A.;
RT   "Cytogenetic study of a new Ph1-positive cell line (NALM-1).";
RL   J. Natl. Cancer Inst. 59:833-837(1977).
//
RX   PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9;
RA   Keating A.;
RT   "Ph positive CML cell lines.";
RL   Baillieres Clin. Haematol. 1:1021-1029(1987).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=9067587; DOI=10.1038/sj.leu.2400571;
RA   Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A.,
RA   Janssen J.W.G., Drexler H.G.;
RT   "Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in
RT   human early B-lineage leukemia cell lines.";
RL   Leukemia 11:441-447(1997).
//
RX   PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2;
RA   Matsuo Y., Drexler H.G.;
RT   "Establishment and characterization of human B cell precursor-leukemia
RT   cell lines.";
RL   Leuk. Res. 22:567-579(1998).
//
RX   PubMed=12506034; DOI=10.1182/blood-2002-06-1770;
RA   Uno K., Inukai T., Kayagaki N., Goi K., Sato H., Nemoto A.,
RA   Takahashi K., Kagami K., Yamaguchi N., Yagita H., Okumura K.,
RA   Koyama-Okazaki T., Suzuki T., Sugita K., Nakazawa S.;
RT   "TNF-related apoptosis-inducing ligand (TRAIL) frequently induces
RT   apoptosis in Philadelphia chromosome-positive leukemia cells.";
RL   Blood 101:3658-3667(2003).
//
RX   PubMed=15588857; DOI=10.1016/j.cancergencyto.2004.04.021;
RA   Pelz A.-F., Weilepp G., Wieacker P.F.;
RT   "Re-analysis of the cell line NALM-1 karyotype by GTG-banding,
RT   spectral karyotyping, and whole chromosome painting.";
RL   Cancer Genet. Cytogenet. 156:59-61(2005).
//
RX   PubMed=15843827; DOI=10.1038/sj.leu.2403749;
RA   Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J.,
RA   Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M.,
RA   Fioretos T.;
RT   "Gene expression profiling of leukemic cell lines reveals conserved
RT   molecular signatures among subtypes with specific genetic
RT   aberrations.";
RL   Leukemia 19:1042-1050(2005).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//